Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature.
Forty-two patients with measureable, advanced, genito-urinary cancer received Adriamycin. Significant clinical responses (CR/PR) occurred in only five (14%) of 35 adequately treated patients. Four additional patients achieved a minimal response anf four others showed stabilization of their disease for 4 to 9 months. Review of the literature suggests an overall response rate of 20%. Patients with a urinary diversion lived significantly longer (P 0.006) than patients who did not have this procedure (42.5 months vs 21.5 months). The need to define various patient characteristics in future chemotherapeutic trials in bladder cancer is discussed.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000601:surgery; D000328:Adult; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000601:surgery; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012075:Remission, Spontaneous; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery; D014547:Urinary Diversion; D014565:Urogenital Neoplasms / Q000188:drug therapy* / Q000601:surgery
D004317:Doxorubicin